The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Cogent Biosciences Inc shares valued at $127,400,000 were sold by Fairmount Funds Management LLC on Jan 22 ’26. At $36.40 per share, Fairmount Funds Management LLC sold 3,500,000 shares. The insider’s holdings dropped to 5,503,418 shares worth approximately $217.55 million following the completion of this transaction.
Also, Fairmount Healthcare Fund II L purchased 3,500,000 shares, netting a total of over 127,400,000 in proceeds.
Before that, Kearns Evan had sold 65,000 shares from its account. In a trade valued at $2,515,500, the Chief Legal Officer traded Cogent Biosciences Inc shares for $38.70 each. Upon closing the transaction, the insider’s holdings decreased to 65,000 shares, worth approximately $4.32 million.
As published in a research note from Wedbush on November 10, 2025, Cogent Biosciences Inc [COGT] has been rated up from a Neutral to an Outperform and the price target has been revised to $38. Analysts at Stifel upgraded the stock from ‘”a Hold”‘ to ‘”a Buy”‘ outlook in a report released in early November. As of October 16, 2025, Stifel has initiated its “Hold” rating for COGT. Earlier on September 03, 2025, Raymond James initiated its rating. Their recommendation was “a Strong buy” for COGT stock.
Analyzing COGT Stock Performance
On last trading session, Cogent Biosciences Inc [NASDAQ: COGT] plunged -0.93% to $39.53. The stock’s lowest price that day was $39.29, but it reached a high of $40.385 in the same session. During the last five days, there has been a surge of approximately 4.60%. Over the course of the year, Cogent Biosciences Inc shares have jumped approximately 382.07%.
Is Cogent Biosciences Inc subject to short interest?
Stocks of Cogent Biosciences Inc saw a sharp rise in short interest on 2025-12-31 jumping by 0.96 million shares to 15.13 million. Data from Yahoo Finance shows that the short interest on 2025-11-28 was 14.17 million shares. A jump of 6.33% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 5.92 of the overall float, the days-to-cover ratio (short ratio) jumped to 5.92.
Which companies own the most shares of Cogent Biosciences Inc (COGT)?
In terms of Cogent Biosciences Inc share price expectations, FactSet research, analysts set an average price target of 48 in the next 12 months, up nearly 20.3% from the previous closing price of $39.9. Analysts anticipate Cogent Biosciences Inc stock to reach 60 by 2026, with the lowest price target being 20. In spite of this, 4 analysts ranked Cogent Biosciences Inc stock as Buy at the end of 2026. On March 07, 2025, Scotiabank assigned a price target of “a Sector outperform” to the stock and initiated coverage with a $17.
